GBIO vs. ENTA, EDIT, NLTX, PROC, NMRA, LXEO, TIL, SNTI, RAPT, and CCCC
Should you be buying Generation Bio stock or one of its competitors? The main competitors of Generation Bio include Enanta Pharmaceuticals (ENTA), Editas Medicine (EDIT), Neoleukin Therapeutics (NLTX), Procaps Group (PROC), Neumora Therapeutics (NMRA), Lexeo Therapeutics (LXEO), Instil Bio (TIL), Senti Biosciences (SNTI), RAPT Therapeutics (RAPT), and C4 Therapeutics (CCCC). These companies are all part of the "pharmaceutical products" industry.
Generation Bio vs.
Generation Bio (NASDAQ:GBIO) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations, risk and community ranking.
95.2% of Generation Bio shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 21.1% of Generation Bio shares are owned by company insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Generation Bio presently has a consensus target price of $7.33, indicating a potential upside of 1,643.54%. Enanta Pharmaceuticals has a consensus target price of $17.25, indicating a potential upside of 204.23%. Given Generation Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Generation Bio is more favorable than Enanta Pharmaceuticals.
Enanta Pharmaceuticals received 273 more outperform votes than Generation Bio when rated by MarketBeat users. However, 72.31% of users gave Generation Bio an outperform vote while only 56.94% of users gave Enanta Pharmaceuticals an outperform vote.
Enanta Pharmaceuticals has a net margin of -157.57% compared to Generation Bio's net margin of -782.86%. Enanta Pharmaceuticals' return on equity of -75.53% beat Generation Bio's return on equity.
Enanta Pharmaceuticals has higher revenue and earnings than Generation Bio. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Generation Bio, indicating that it is currently the more affordable of the two stocks.
Generation Bio has a beta of 2.78, indicating that its stock price is 178% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than Generation Bio. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for Generation Bio. Enanta Pharmaceuticals' average media sentiment score of 1.71 beat Generation Bio's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
Summary
Enanta Pharmaceuticals beats Generation Bio on 10 of the 18 factors compared between the two stocks.
Get Generation Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Generation Bio Competitors List
Related Companies and Tools
This page (NASDAQ:GBIO) was last updated on 4/25/2025 by MarketBeat.com Staff
